Patents by Inventor Anand R. Baichwal

Anand R. Baichwal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained release formulations of nalbuphine
    Patent number: 10406106
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 10, 2019
    Assignee: ENDO PHARMACEUTICALS INC.
    Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler, David Verbel, Stanley Au
  • SUSTAINED RELEASE FORMULATIONS OF NALBUPHINE
    Publication number: 20190117576
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Application
    Filed: November 21, 2018
    Publication date: April 25, 2019
    Inventors: Anand R. BAICHWAL, Philip A. GOLIBER, Anthony E. CARPANZANO, Thomas SCIASCIA, Donald DIEHL, Brian VOGLER, David VERBEL, Stanley AU
  • Sustained release formulation of nalbuphine
    Patent number: 10172798
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: January 8, 2019
    Assignee: Endo Pharmaceuticals Inc.
    Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler, David Verbel, Stanley Au
  • OXYMORPHONE CONTROLLED RELEASE COMPOSITIONS
    Publication number: 20180338967
    Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
    Type: Application
    Filed: July 30, 2018
    Publication date: November 29, 2018
    Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
  • SUSTAINED RELEASE FORMULATION OF NALBUPHINE
    Publication number: 20180042852
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Application
    Filed: July 24, 2017
    Publication date: February 15, 2018
    Inventors: Anand R. BAICHWAL, Philip A. GOLIBER, Anthony E. CARPANZANO, Thomas SCIASCIA, Donald DIEHL, II, Brian VOGLER, David VERBEL, Stanley AU
  • Oxymorphone controlled release formulations
    Patent number: 9820982
    Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphine which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: November 21, 2017
    Assignee: ENDO PHARMACEUTICALS INC.
    Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
  • SUSTAINED RELEASE FORMULATION OF NALBUPHINE
    Publication number: 20160263035
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Application
    Filed: May 23, 2016
    Publication date: September 15, 2016
    Applicant: Endo Pharmaceuticals Inc.
    Inventors: Anand R. BAICHWAL, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler, David Verbel, Stanley Au
  • Sustained release formulation of nalbuphine
    Patent number: 9351938
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: May 31, 2016
    Assignee: ENDO PHARMACEUTICALS INC
    Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler, David Verbel, Stanley Au
  • OXYMORPHONE CONTROLLED RELEASE COMPOSITIONS
    Publication number: 20160136152
    Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
    Type: Application
    Filed: July 14, 2015
    Publication date: May 19, 2016
    Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
  • Chronotherapeutic dosage forms
    Patent number: 9278076
    Abstract: A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: March 8, 2016
    Assignee: Endo Pharmaceuticals Inc.
    Inventors: Anand R. Baichwal, Paul Woodcock, Steve Labudzinski
  • Sustained release formulation of nalbuphine
    Patent number: 9186330
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: November 17, 2015
    Assignee: Endo Pharmaceuticals INC.
    Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler
  • OXYMORPHONE CONTROLLED RELEASE FORMULATIONS
    Publication number: 20150011577
    Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
  • SUSTAINED RELEASE FORMULATION OF NALBUPHINE
    Publication number: 20140315937
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 23, 2014
    Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler
  • SUSTAINED RELEASE FORMULATION OF NALBUPHINE
    Publication number: 20140271852
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Application
    Filed: May 29, 2014
    Publication date: September 18, 2014
    Applicant: PENWEST PHARMACEUTICALS CO.
    Inventors: Anand R. BAICHWAL, Philip A. GOLIBER, Anthony E. CARPANZANO, Thomas SCIASCIA, Donald DIEHL, II, Brian VOGLER, David VERBEL, Stanley AU
  • SUSTAINED RELEASE MATRIX SYSTEMS FOR HIGHLY SOLUBLE DRUGS
    Publication number: 20140242166
    Abstract: Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients.
    Type: Application
    Filed: March 3, 2014
    Publication date: August 28, 2014
    Applicant: Penwest Pharmaceuticals Co.
    Inventors: Anand R. Baichwal, Troy W McCALL, Lirong LlU, Steve LABUDZINSKI
  • Sustained release formulations of nalbuphine
    Patent number: 8771732
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: July 8, 2014
    Assignee: Endo Pharmaceuticals Inc
    Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler
  • Sustained release formulation of nalbuphine
    Patent number: 8765175
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: July 1, 2014
    Assignee: Endo Pharmaceuticals Inc
    Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler, David Verbel, Stanley Au
  • OXYMORPHONE CONTROLLED RELEASE FORMULATIONS
    Publication number: 20140134250
    Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
    Type: Application
    Filed: June 3, 2013
    Publication date: May 15, 2014
    Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
  • Sustained release matrix systems for highly soluble drugs
    Patent number: 8679535
    Abstract: Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: March 25, 2014
    Assignee: Endo Pharmaceuticals Inc.
    Inventors: Anand R. Baichwal, Troy W. McCall, Lirong Liu, Steve Labudzinski
  • Sustained release formulations of nalbuphine
    Patent number: 8394812
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: March 12, 2013
    Assignee: Penwest Pharmaceuticals Co.
    Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler, David Verbel, Stanley Au